John Johnson
CIK 1410781 · Executive Chairman · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AXGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1301 2ND AVENUE
SEATTLE, WA 98101
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| AXGN | Director | 14,150 | $36.13 | $511.2K | -$1.91M | 12 | 2026-06-26 |
| XERS | Director | 683,083 | $10.48 | $7.16M | -$1.85M | 10 | 2026-06-05 |
| VSTM | Director | 52,666 | $8.38 | $441.3K | $0 | 10 | 2026-05-26 |
| Applied Therapeutics, Inc. (APLT) Delisted | Executive Chairman | 500,000 | $0.10 | $51.5K | $0 | 1 | 2024-12-20 |
| Strongbridge Biopharma plc (SBBP) Delisted | Chief Executive Officer | 0 | $2.00 | $0 | $0 | 11 | 2021-10-06 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 0 | — | — | $0 | 8 | 2020-07-02 |
| MELINTA THERAPEUTICS, INC. /NEW/ (MLNT) Delisted | Chief Executive Officer | 37,400 | — | — | -$72.4K | 5 | 2019-07-02 |
| Sucampo Pharmaceuticals, Inc. (SCMP) Delisted | Director | 0 | — | — | $0 | 5 | 2018-02-13 |
| AVEO PHARMACEUTICALS, INC. (AVEO) Delisted | Director | — | $15.00 | — | $0 | 1 | 2018-02-05 |
| MELINTA THERAPEUTICS, INC. /NEW/ (CEMP) Delisted | Director | 10,000 | — | — | $0 | 6 | 2017-01-05 |
| Ocera Therapeutics, Inc. (TZYM) Delisted | Director | — | — | — | $0 | 2 | 2012-08-09 |
| SAVIENT PHARMACEUTICALS INC (SVNT) Delisted | Chief Executive Officer | 256,350 | — | — | $110.5K | 6 | 2012-01-04 |
| IMCLONE SYSTEMS INC (IMCL) Delisted | CEO | 0 | — | — | $500.0K | 4 | 2008-11-24 |
Recent Filings · Page 4 of 11
104 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-12-20 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | VSTM | Grant (A) | — | $0 | EDGAR |
| 2022-06-09 | XERS | Grant (A) | +15,000 | $0 | EDGAR |
| 2022-06-03 | AXGN | Grant (A) | — | $0 | EDGAR |
| 2021-10-08 | XERS | Grant (A) | +478,312 | $0 | EDGAR |
| 2021-10-06 | Strongbridge Biopharma plc (SBBP) Delisted | Disp (D) | −610,092 | $0 | EDGAR |
| 2021-10-05 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −334,868 | -$689.8K | EDGAR |
| 2021-10-05 | — | Grant (A) | +478,312 | $0 | |
| 2021-07-21 | AXGN | Grant (A) | — | $0 | EDGAR |
| 2021-07-07 | Strongbridge Biopharma plc (SBBP) Delisted | Tax (F) | −50,867 | -$156.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.